- GSK to advance genomic research and improve drug discovery
- BlackStone Therapeutics closes $76 m Series B financing
- Novartis continues to innovate in CML
- Dr. Reddy's enters into a definitive agreement to sell its neurology branded products to Upsher Smith Laboratories
- AllMed Healthcare Management joins fight to end opioid epidemic
- Sun Pharma’s ILUMYA improves joint and skin symptoms of Psoriatic Arthritis
- Lumosa to Initiate Phase 2 Human Clinical Trial for LT3001 to treat Acute Ischemic Stroke
- Biocon Biologics receive EU GMP Certification
- First Uzbekistani Company in Hong Kong to bring Chinese Medicine Business along "The Belt and Road"
- 111 Partners with Tong Ren Tang Technologies to Advance "Internet + Healthcare"
- China NMPA Approves Sinovant's Clinical Trial Application for Lefamulin
- Terns Pharmaceuticals and Shanghai Tuosheng Biotechnology initiate TERN-101 first phase trial
- IBM, KPMG, Merck and Walmart to evaluate the use of blockchain in pharma
- Inaugural Global Health Forum of Boao Forum for Asia held in China
-
Singapore | 27 May 2019 | News
A Nutrition Pathway to Stamp out the Start of Cancer
In a landmark study, scientists at the Agency of Science, Technology and Research’s (A*STAR) Genome Inst...Read more
Japan | 24 May 2019 | News
Scientists develop technique for better detection of breast cancer
Researchers at Okayama University report in the journal Sensors and Actuators B: Chemical that terah...Read more
-
World | 14 June 2019 | News
Novartis continues to innovate in CML
Long-term follow-up data from the ongoing, pivotal open-label ENESTfreedom and ENESTop trials showed sustained...Read more
-
World | 14 June 2019 | News
GSK to advance genomic research and improve drug discovery
GlaxoSmithKline plc has announced a five-year collaboration with the University of California to establish a s...Read more
-
Japan | 28 May 2019 | News
B dot Medical to develop ultra-compact proton cancer therapy
Japan based B dot Medical Inc. has announced that the company has initiated the development of an ultra-c...Read more
-
China | 28 May 2019 | News
Collaboration to establish comprehensive pharma, health system
Following 111, Inc.'s strategic partnership with Manulife-Sinochem last year, the Company has reached ano...Read more
ASIA-PACIFIC: MODEST RISE IN HEALTHCARE DEALS
Healthcare private equity tends to be less vulnerable to downturns than other sectors, so it expects demand for assets in Asia-Pacific to increase over the coming years. Buyout funds will invest more in growth-stage assets such as Chinese pharma. And as companies explore ways to increase access to healthcare, emerging trends, such as digital healthcare solutions, should gain steam in China, India and other countries. Investors will continue to seek deals in the provider and medtech sectors, and explore creative ways to deploy capital, such as public-toprivate takeovers. Baker McKenzie Global Transactions Forecast predicts a modest rise of 7 per cent in deals to $331 billion in 2019, as a number of cross-border and domestic megadeals are set to close.
